The state of Florida currently has 5 active clinical trials seeking participants for Primary Sclerosing Cholangitis research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/13/2024
Locations: Florida Research Institute, Lakewood Ranch, Florida +2 locations
Conditions: Primary Sclerosing Cholangitis
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Recruiting
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the stud... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/31/2024
Locations: Schiff Center for Liver Diseases - University of Miami, Miami, Florida +1 locations
Conditions: Primary Sclerosing Cholangitis
Vancomycin for Primary Sclerosing Cholangitis
Recruiting
To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis. Funding Source - FDA OOPD
Gender:
All
Ages:
Between 18 years and 76 years
Trial Updated:
04/17/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Primary Sclerosing Cholangitis
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Recruiting
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2024
Locations: University of Miami Health System, Miami, Florida
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis
Liver Cirrhosis Network Cohort Study
Recruiting
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: University of Miami Health System, Miami, Florida
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis